Your shopping cart is currently empty

XJTU-L453, a PI3Kα inhibitor, exhibits an IC50 of 0.4 nM. It inhibits the proliferation of breast cancer cell lines T47D and MCF7, with IC50 values of 0.2 μM and 0.5 μM respectively. Additionally, XJTU-L453 disrupts the PI3K pathway, leading to cell cycle arrest and cell apoptosis (apoptosis). It also demonstrates antitumor activity in MCF7 xenograft mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,670 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $2,180 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $2,800 | 8-10 weeks | 8-10 weeks |
| Description | XJTU-L453, a PI3Kα inhibitor, exhibits an IC50 of 0.4 nM. It inhibits the proliferation of breast cancer cell lines T47D and MCF7, with IC50 values of 0.2 μM and 0.5 μM respectively. Additionally, XJTU-L453 disrupts the PI3K pathway, leading to cell cycle arrest and cell apoptosis (apoptosis). It also demonstrates antitumor activity in MCF7 xenograft mice. |
| Molecular Weight | 390.44 |
| Formula | C22H22N4O3 |
| Cas No. | 3008290-92-1 |
| Smiles | O([C@H](C(N)=O)C)C=1C=C2C(C=3C(CO2)=CC=C(C3)C=4C=C(NCC)N=CN4)=CC1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.